VisualCV

Xeo means "innovative ideas that have yet to be discovered" and at XeoTK we are dedicated to bringing innovative software solutions to clinical research professionals.

Our goal is to support effective work practices, improve efficiency while eliminating frustration. How do we do this? We work directly with all stakeholders in the clinical research process, from clinical research sites to sponsors. Real users guide us in the development of practical solutions to the clinical development of pharmaceuticals, biologics and medical devices.

START UP

Venture backed online life sciences information and research firm for physicians and biomedical scientists.

• Wrote business plan and presented to Venture Capitalists securing $1.1 million in Series A financing.
• Developed global database of 200K scientists, implemented lead generation securing advertising revenue from major life science firms. Increased monthly users to over 125K with SEM/SEO technologies.
• Chairman of the Board of Directors. Established dynamic leadership team.

Result:  Sold firm to a private equity group creating new research company, member of Advisory Board.

International B2B clinical informatics company ($25million revenues) providing analytics, consulting and database services (to the top 50 pharmaceutical and biotech firms) and medical education products to physicians (subsidiary of $12 billion Rogers Communications Inc.)

• Expanded “capacity” in New York, merged European and North American operations into the U.S. head office resulting in substantial savings and a 30% increase in profits

• With this tighter focus, changed name from Medical Education Network to Rogers Medical Intelligence Solutions and expanded North American and European sales force presence

• Re-engineered global database architecture to increase new products and greater customer focus and expanded revenue 30% with dramatic EBITDA improvements

• Implemented international accounting/finance system to improve performance measurement

• Recognizing lack of synergy with parent, recommended to Board to seek strategic options to maximize shareholder value. Wrote Information Memorandum, met with investors (VC/Private Equity, Fortune 200)

Result:  Secured six different offers and negotiated sale of Company in June 2006 to Jobson Medical Information 

START UP                                                                                                   
Medical device and Informatics Company focused on B2B healthcare market providing physicians with real- time diagnostic imaging data linked to patient-specific medical information during treatment.                           

• Developed web product offerings to diagnostic imaging centers and physicians and services to the pharmaceutical/biotech/medical device industries; participated in capitalization initiatives.
• Wrote 510(k) submission and secured FDA approval for the Medeview System

Result: Company was acquired by Source Medical in 2002 .

START UP JV

Joint venture and first global company to research, develop, and commercialize transgenic trees. Joint venture between 4 leading genomic and forest biotechnology firms, including a Fortune 50 corporation, with $60 million of seed capital in place.
Strategic Biotech Board Consultant

• Retained by Board to form a joint venture (the 4 partners had been discussing collaboration for a number of years but needed an outsider to facilitate it).
• Joint venture agreement created and executed, IP and R&D licensing agreements completed.
• Redirected the coordination of R&D efforts; proposed a Strategic Enterprise Management process to accelerate new products and create transparency among the 4 participants.
• Developed corporate name and logo (ArboGen)
• Initiated marketing program, including creating press releases and public relations campaign on Genetically Modified Organisms. 

Result:  After 3 months, the legal and business structures were established to enable the ArboGen JV to be launched

GROWTH                                                                     
$20 million pharmaceutical company (subsidiary of public company, Lavipharm, Athens, Greece), specializing in R&D of transdermal/epidermal and transmucosal patches for the pharmaceutical, OTC, and cosmetic industries. Products are sold internationally through licensing partners. 

• Recruited by Board of Directors to develop strategic plan and infrastructure, hirer a world class scientific and management team, and position the Company for an eventual IPO in the U.S.:
• Secured 50,000 ft² headquarters facility, structured Company and focused on new product development, especially pharmaceuticals, cosmeceuticals, and new technologies.  Transferred R&D technology from Greece to U.S.
• Increased staff 10-fold, hiring 40 personnel, including 8 Ph.D.s, Director of Product Development, and Vice Presidents of Regulatory Affairs, R&D, and Finance
• Developed a number of new products (for example, a pressure-sensitive nose patch, 2 forms of transmucosal patches, an osteoporosis patch)
• Applied for 2 new patents and initiated 3 trademark registrations.  Conducted U.S. and European patent-infringement opinion on Nitroglycerine and Estradiol; provided regulatory counsel to potential customers on OTC and cosmetic regulations In so doing, elevated Company’s presence in U.S. market.

Result: Made numerous presentations to prospective investment bankers for IPO. Lehman Brothers retained and prospectus completed  for SEC filing (which for various reasons “never got off the ground”)

TRANSFORMATIONAL CHANGE                                       
$1billion market cap biopharmaceutical company based on lipid biochemistry and photodynamic therapy.
Managing Director of Worldwide Commercial Operations and Corporate Director 

Based in Sterling, Scotland; recruited to provide commercial credibility to a R&D company:

• In order to provide investors and the market with a dynamic strategy and business plan, structured Company into 4 operating divisions (Pharmaceuticals, Photodynamic Therapy, Functional Foods, Nutritionals) and appointed a managing director for each
• Established presence in Asia and Japan; strengthened global licensing and new business development initiatives; introduced global planning process for all corporate functions; established evaluation process for products moving into Phase I and Phase III, thereby ensuring strategic resource allocations
• Obtained Company’s first U.S. IND 
• Worked with investment bankers Robert Fleming, Hoare Govett, Dresdner Kleinwort Benson, on corporate financing, licensing, and asset divestiture. Director at shareholder meetings

Result: Increased sales 15%, raised $110 million in milestones and advance royalty payments through out-licensing agreements, divested non-core assets, generating $27 million